The authors wish to thank Janet Shannon for her excellent study coordinator support for this trial.
Mr. Luo and Hornby and Drs. Christiansen, Chow Maneval, and Multani have disclosed that they are employed by and own equity in Ignyta. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
The patient described in this case report signed an informed consent form and was enrolled in the STARTRK-2 (RXDX-101-02) trial sponsored by Ignyta, Inc. at Scripps Clinic (IRB Number: IRB-15-6698).
YaoJCHassanMPhanA. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol2008;26:3063–3072.
KlimstraDSBeltranHLilenbaumRBergslandE. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book2015:92–103.
KimDHNaganoYChoiIS. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer2008;47:84–92.
KulkeMHFreedEChiangDY. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer2008;47:591–603.
LöllgenRMHessmanOSzaboE. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer2001;92:812–815.
NaganoYKimDHZhangL. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer2007;14:483–492.
ObergK. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes2009;16:72–78.
XavierSRosaBCotterJ. Small bowel neuroendocrine tumors: from pathophysiology to clinical approach. World J Gastrointest Pathophysiol2016;7:117–124.
ChandrasekharappaSCGuruSCManickamP. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science1997;276:404–407.
CorboVDalaiIScardoniM. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer2010;17:771–783.
JiaoYShiCEdilBH. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science2011;331:1199–1203.
RajNPSoumeraiTValentinoE. Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): a study using MSK-IMPACT [abstract]. J Clin Oncol2016;34(Suppl):Abstract e15661.
MurphyDAElyHAShoemakerR. Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol2017;25:513–523.
MeldrumCDoyleMATothillRW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev2011;32:177–195.
DrilonADe BraudFGSienaS. Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: updated phase I results [abstract]. Cancer Res2016;76(14 Suppl):Abstract CT007.